Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Invivyd Inc (IVVD)

Invivyd Inc (IVVD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 367,373
  • Shares Outstanding, K 282,595
  • Annual Sales, $ 53,430 K
  • Annual Income, $ -52,490 K
  • EBIT $ -56 M
  • EBITDA $ -53 M
  • 60-Month Beta 0.73
  • Price/Sales 6.77
  • Price/Cash Flow N/A
  • Price/Book 1.28

Options Overview Details

View History
  • Implied Volatility 181.35% (+43.68%)
  • Historical Volatility 84.41%
  • IV Percentile 40%
  • IV Rank 9.56%
  • IV High 1,010.24% on 06/27/25
  • IV Low 93.77% on 01/08/26
  • Expected Move (DTE 10) 0.2975 (23.06%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 370
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 19,552
  • Open Int (30-Day) 22,595
  • Expected Range 0.9925 to 1.5875

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 1
  • High Estimate $-0.08
  • Low Estimate $-0.08
  • Prior Year $-0.14
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1700 +8.12%
on 03/30/26
2.0400 -37.99%
on 03/10/26
-0.5350 (-29.72%)
since 03/06/26
3-Month
1.1700 +8.12%
on 03/30/26
2.7800 -54.50%
on 01/09/26
-1.1350 (-47.29%)
since 01/07/26
52-Week
0.4613 +174.23%
on 04/16/25
3.0699 -58.79%
on 11/17/25
+0.7531 (+147.12%)
since 04/07/25

Most Recent Stories

More News
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health

National education campaign aims to educate Americans about antibodies and their role in immune health Campaign centerpiece, AntibodiesforAnyBody.com , offers an interactive immune health wellness...

IVVD : 1.2290 (-5.46%)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on April 1, 2026, Invivyd granted 16 newly hired non-executive employees options to purchase an...

IVVD : 1.2290 (-5.46%)
Invivyd Announces Presentation at the World Vaccine Congress Washington

Chief Scientific Officer, Robert Allen, Ph.D., presented as part of the “Antibodies for Infectious Disease Workshop” at the World Vaccine Congress Washington Presentation titled “Developing mAb...

IVVD : 1.2290 (-5.46%)
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Achieved Q4 2025 PEMGARDA ® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter 2025 year-end cash and cash equivalents of...

IVVD : 1.2290 (-5.46%)
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital,...

IVVD : 1.2290 (-5.46%)
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced...

IVVD : 1.2290 (-5.46%)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an...

IVVD : 1.2290 (-5.46%)
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published...

IVVD : 1.2290 (-5.46%)
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to...

IVVD : 1.2290 (-5.46%)
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention

The educational campaign will focus on teaching the American public about antibodies and preventing infectious disease The collaboration will advance public understanding of antibodies as a centerpiece...

IVVD : 1.2290 (-5.46%)

Business Summary

INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 1.4599
2nd Resistance Point 1.4199
1st Resistance Point 1.3600
Last Price 1.2290
1st Support Level 1.2601
2nd Support Level 1.2201
3rd Support Level 1.1602

See More

52-Week High 3.0699
Fibonacci 61.8% 2.0734
Fibonacci 50% 1.7656
Fibonacci 38.2% 1.4578
Last Price 1.2290
52-Week Low 0.4613

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.